Abaloparatide
Abaloparatide, sold under the brand name Tymlos among others, is a parathyroid hormone-related protein (PTHrP) analogue medication used to treat osteoporosis.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Abaloparatide, sold under the brand name Tymlos among others, is a parathyroid hormone-related protein (PTHrP) analogue medication used to treat osteoporosis. It is an anabolic (i.e., bone growing) agent. The most common side effects include hypercalciuria (high calcium levels in the urine) and dizziness.
Other common side effects include back pain, nausea, headache, joint pain, high blood pressure, reactions at the injection site, and palpitations (a forceful heartbeat that may be rapid or irregular). Abaloparatide was approved for medical use in the United States in April 2017, and in the European Union in December 2022. Phase II trials were initiated in 2008.
A 24-week randomized trial was conducted in postmenopausal women with osteoporosis (n=222) assessing bone mass density (BMD) changes as the primary endpoint. Significant BMD increase at doses of 40 and 80 mcg were found in the lumbar spine, femur and hips of abaloparatide-treated participants compared to placebo.
Additionally, abaloparatide showed superior anabolic effects on the hips compared to teriparatide. In the phase III (2011-2014) Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, an 18-months randomized, multicenter, double-blinded, placebo-controlled study evaluated the long-term efficacy of abaloparatide compared to placebo and teriparatide in 2,463 postmenopausal women (mean age 69 years).
Women who received daily injections of abaloparatide experienced substantial reduction in the incidence of fractures compared to placebo. Additionally, greater BMD increase at 6, 12 and 18 months in spinal, hips and femoral bones was observed in abaloparatide compared to placebo and teriparatide-treated subjects.
Participants who completed 18 months of abaloparatide or placebo in the ACTIVE study were invited to participate in an extended open-labeled study - ACTIVExtend study (2012-2016). Subjects (n=1139) received additional 2 years of 70 mg of alendronate, Vitamin D (400 to 800 IU), and calcium (500–1000 mg) supplementation daily.
Combined abaloparatide and alendronate therapy reduced significantly the incidence of vertebral and nonvertebral fractures. In addition to the injectable form of abaloparatide, a transdermal patch is also in development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374491090 under CC BY-SA 4.0; modifications have been made.